Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy

The American Journal of the Medical Sciences
Soghra RabizadehAlireza Esteghamati

Abstract

This study was designed to comparatively assess the effects of add-on pentoxifylline to losartan versus increasing the dose of losartan on serum N-terminal pro-brain natriuretic peptide (NT-proBNP), serum highly sensitive C-reactive protein (hsCRP) and the urinary albumin excretion (UAE) rate in patients with type 2 diabetes and nephropathy. In an open-label, single-center, parallel-group, randomized clinical trial (NCT03006952), 30 patients received b.i.d. dose of pentoxifylline 400mg plus daily dose of losartan 50mg (pentoxifylline arm) and 29 patients received b.i.d. dose of losartan 50mg (losartan arm) during a 12-week follow-up period. Serum NT-proBNP, serum hsCRP and UAE levels all significantly decreased from baseline in both trial arms. The pentoxifylline and losartan trial arms were equally effective in reducing serum NT-proBNP levels during the course of trial (multivariable adjusted model P value = 0.864, effect size = 0.2%). There was a greater decrease in UAE and serum hsCRP levels in the pentoxifylline arm (P = 0.034, effect size = 7.8%; P = 0.009, effect size = 11.7%, respectively). Conversely, patients in the losartan arm achieved better systolic and diastolic blood pressure control (P < 0.001, effect size = 25....Continue Reading

References

Jun 27, 2002·Vascular Medicine·Jay P Garg, George L Bakris
Jun 28, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Juan F NavarroJavier Garca
Dec 24, 2004·Diabetes Care·Jorge L GrossThemis Zelmanovitz
Mar 4, 2006·Kidney International·H Birn, E I Christensen
Sep 17, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Yasufumi DoiYutaka Kiyohara
Oct 25, 2011·Diabetes Research and Clinical Practice·Ramazan DanisOmer Alyan
Jun 19, 2012·The Korean Journal of Internal Medicine·Shin-Wook Kang
May 18, 2013·The Korean Journal of Internal Medicine·Shailendra Kapoor
Jun 28, 2014·Journal of the American Society of Nephrology : JASN·Juan F Navarro-GonzálezJavier García
Jan 22, 2015·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·A EsteghamatiM Nakhjavani
Feb 27, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Mohsen AfaridehAlireza Esteghamati
Apr 19, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Hiddo J Lambers Heerspink, Ron T Gansevoort
Feb 13, 2016·Open Heart·Mark F McCartyJames J DiNicolantonio
Feb 29, 2016·Journal of Diabetes and Its Complications·Lingli ZhouLinong Ji
Apr 21, 2016·Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques·Cody CarsonBrian Shepler
Apr 24, 2016·Annales d'endocrinologie·Alireza EsteghamatiManouchehr Nakhjavani
Apr 25, 2016·Annals of Global Health·Sina NoshadAlireza Esteghamati
Jan 1, 2017·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Amin IrannejadAlireza Esteghamati
Feb 10, 2017·Irish Journal of Medical Science·A EsteghamatiM Afarideh

❮ Previous
Next ❯

Citations

Aug 3, 2019·International Journal of Endocrinology and Metabolism·Soghra RabizadehAlireza Esteghamati
Sep 7, 2019·Journal of Clinical Pharmacology·Hossein NamdarTaher Entezari-Maleki
May 16, 2020·Drug Discovery Today·Frederikke E SembachLisbeth N Fink
Jun 22, 2021·Diabetology International·Sepideh BabaniamansourMahtab Niroomand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.